This study introduced MMVR as a new imaging biomarker highlighting its ability to noninvasively reveal increased PD-L1 expression in tumor thus predicting clinical benefit from checkpoint blockade in NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.